Business
Medincell Launches a Private Placement for International Institutional Investors
MONTPELLIER, France, March 05, 2026--Regulatory News: THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA
About this update from Medincell Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1772,"height":295,"url":"https://media.zenfs.com/en/business-wire.com/80f3603fc19242fe90e65e06bfc5ec6f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.GYHVFTar4OQwUTFxL6ERw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/80f3603fc19242fe90e65e06bfc5ec6f","width":960,"height":160},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/CsiPaxyDFdE9lju2DcrQ3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/80f3603fc19242fe90e65e06bfc5ec6f","width":1200,"height":200}},"lazy":false},{"type":"text","content":"The Private Placement, of approximately 6% of the Company’s share capital, is aimed at international institutional investors, through an accelerated book-building process.","length":171,"tagName":"p"},{"type":"text","content":"Funds raised are expected to support long‑term value creation, primarily by expanding partnering opportunities, maximizing the value captured from future collaborations, and strengthening Medincell’s proprietary long‑acting injectable (LAI) technology platform through targeted innovation.","length":289,"tagName":"p"},{"type":"text","content":"MONTPELLIER, France, March 05, 2026--(BUSINESS WIRE)--Regulatory News:","length":70,"tagName":"p"},{"type":"text","content":"THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA","length":177,"tagName":"p","attribs":{}},{"type":"text","content":"Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the "Company"), today announced the launch of a private placement of approximately 6% of the Company’s share capital, targeted at international institutional investors through an accelerated book‑building process.","length":373,"tagName":"p"},{"type":"text","content":"The net proceeds from the private placement, together with the Company’s existing cash resources, are expected to support and accelerate the execution of Medincell’s growth strategy.","length":182,"tagName":"p"},{"type":"text","content":"In particular, t...